DHA effects in Parkinson disease depression

Basal Ganglia

Volumn 4, Issue 2, 2014, Pages 61-66

  Pomponi, M ^a,b   Loria, G ^a   Salvati, S ^c   Di Biase, A ^c   Conte, G ^a   Villella, C ^a   Righino, E ^a   Ciciarelli, C ^a   Bria, P ^a   La Torre, G ^d   Pomponi, M F L ^a   Janiri, L ^a   Bentivoglio, A R ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Achille e Linda Lorenzon Foundation   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Depression; Docosahexaenoic acid; Parkinson's disease

Indexed keywords

DOCOSAHEXAENOIC ACID; FATTY ACID; ICOSAPENTAENOIC ACID; PLACEBO;

ADULT; ANHEDONIA; ANXIETY; APATHY; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HOEHN AND YAHR SCALE; HUMAN; MALE; NEUROPROTECTION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 84901849623     PISSN: 22105336     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.baga.2014.03.004     Document Type: Article

References (58)

1. Armento M.E., Stanley M.A., Marsh L., Kunik M.E., York M.K., Bush A.L., et al. Cognitive behavioral therapy for depression and anxiety in Parkinson's disease: a clinical review. J Parkinson's Dis 2012, 2(2):135-151.
2. Janssen C.I., Kiliaan A.J. Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration. Prog Lipid Res 2014, 53:1-17.
3. Hibbeln J.R. Fish consumption and major depression. Lancet 1998, 351(9110):1213.
4. Parker G., Gibson N.A., Brotchie H., Heruc G., Rees A.M., Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am J Psychiatry 2006, 163:969-978.
5. Pawlosky R.J., Hibbeln J.R., Novotny J.A., Salem N. Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans. J Lipid Res 2001, 42:1257-1265.
6. Arterburn L.M., Hall E.B., Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 2006, 83(Suppl. 6):1467S-1476S.
7. He C., Qu X., Cui L., Wang J., Kang J.X. Improved spatial learning performance of fat-1 mice is associated with enhanced neurogenesis and neuritogenesis by docosahexaenoic acid. Proc Natl Acad Sci U S A 2009, 106:11370-11375.
8. Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids 2006, 75:259-269.
9. Yehuda S., Rabinovitz S., Mostofsky D.I. Modulation of learning and neuronal membrane composition in the rat by essential fatty acid preparation: timecourse analysis. Neurochem Res 1998, 23:62734.
10. Kitajka K., Sinclair A.J., Weisinger R.S., Weisinger H.S., Mathai M., Jayasooriya A.P., et al. Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression. Proc Natl Acad Sci U S A 2004, 101:10931-10936.
11. Bernardo A., Minghetti L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr Pharm Des 2006, 12:93-109.
12. Bazan N.G. Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors. Trends Neurosci 2006, 29:263-271.
13. Vreugdenhil M., Bruehl C., Voskuyl R.A., Kang J.X., Leaf A., Wadman W.J. Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons. Proc Natl Acad Sci U S A 1996, 93:12559-12563.
14. Field C.J., Johnson I.R., Schley P.D. Nutrients and their role in host resistance to infection. J Leukoc Biol 2002, 71(1):16-32.
15. Calder P.C. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006, 83(Suppl. 6):1505S-1519S.
16. Ji R.R., Xu Z.Z., Strichartz G., Serhan C.N. Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci 2011, 34(11):599-609.
17. Mori T.A., Beilin L.J. Omega-3 fatty acids and inflammation. Curr Atherosclerosis Rep 2004, 6:461-467.
18. Trebble T.M., Wootton S.A., Miles E.A., et al. Prostaglandin E2 production and T-cell function after fish-oil supplementation: response to antioxidant co-supplementation. Am J Clin Nutr 2003, 78:376-382.
19. Hong S.H., Belayev L., Khoutorova L., Obenaus A., Bazan N.G. Docosahexaenoic acid confers enduring neuroprotection in experimental stroke. J Neurol Sci 2014, 338(1-2):135-141.
20. Lu Y., Zhao L.X., Cao D.L., Gao Y.J. Spinal injection of docosahexaenoic acid attenuates carrageenan-induced inflammatory pain through inhibition of microglia-mediated neuroinflammation in the spinal cord. Neuroscience 2013, 241:22-31.
21. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
22. Serhan C.N., Yacoubian S., Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol 2008, 3:279-312.
23. Vigers A.J., Amin D.S., Talley-Farnham T., Gorski J.A., Xu B., Jones K.R. Sustained expression of brain-derived neurotrophic factor is required for maintenance of dendritic spines and normal behavior. Neuroscience 2012, 212:1-18.
24. Darios F., Davletov B. N-3 and n-6 fatty acids stimulate cell membrane expansion by acting on syntaxin 3. Nature 2006, 440:813-817.
25. Lawson D.L., Mehta J.L., Saldeen K., Mehta P., Saldeen T.G. N-3 polyunsaturated fatty acids augment endothelium-dependent vasorelaxation by enhanced release of EDRF and vasodilator prostaglandins. Eicosanoids 1991, 4:217-223.
26. Lu D.Y., Tsao Y.Y., Leung Y.M., Su K.P. Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: implications of antidepressant effects for ω-3 fatty acids. Neuropsychopharmacology 2010, 35(11):2238-2248.
27. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from Parkinsonian patients. Neurosci Lett 1994, 165:208-210.
28. Mogi M., Harada M., Kondo T., Riederer P., Nagatsu T. Interleukin-2 but not basic fibroblast growth factor is elevated in Parkinsonian brain. J Neural Transm 1996, 103:1077-1081.
29. He C., Qu X., Cui L., Wang J., Kang J.X. Improved spatial learning performance of fat-1 mice is associated with enhanced neurogenesis and neuritogenesis by docosahexaenoic acid. Proc Natl Acad Sci U S A 2009, 106(27):11370-11375.
30. Bazan N.G., Musto A.E., Knott E.J. Endogenous signaling by omega-3 docosahexaenoic acid-derived mediators sustains homeostatic synaptic and circuitry integrity. Mol Neurobiol 2011, 44(2):216-222.
31. Tanskanen A., Hibbeln J.R., Hintikka J., Haatainen K., Honkalampi K., Viinamäki H. Fish consumption, depression, and suicidality in a general population. Arch Gen Psychiatry 2001, 58(5):512-513.
32. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67:446-457.
33. Hashioka S., Klegeris A., Monji A., Kato T., Sawada M., McGeer P.L., et al. Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp Neurol 2007, 206(1):33-42.
34. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
35. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65:32-41.
36. De Berardis D., Conti C.M., Serroni N., Moschetta F.S., Olivieri L., Carano A., et al. The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature. Int J Immunopathol Pharmacol 2010, 23:417-422.
37. Freeman M.P1, Hibbeln J.R., Wisner K.L., Davis J.M., Mischoulon D., Peet M., et al. N-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 2006, 67(12):1954-1967.
38. Hughes A.J., Daniel S.E., Blankson S., Lees A.J. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993, 50(2):140-148.
39. Simon J.A., Fong J., Bernert J.T., Browner W.S. Relation of smoking and alcohol consumption toserum fatty acids. Am J Epidemiol 1996, 144(4):325-334.
40. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
41. Schrag A., Dodel R., Spottke A., Bornschein B., Siebert U., Quinn N.P. Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord 2007, 22(7):938-945.
42. Henkel V., Seemüller F., Obermeier M., Adli M., Bauer M., Mundt C., et al. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord 2009, 115:439-449.
43. Frank E., Prien R., Jarrett R., Keller M., Kupfer D., Lavori P., et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry 1991, 48:851-855.
44. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959, 32:50-55.
45. Leentjens A.F., Dujardin K., Marsh L., Martinez-Martin P., Richard I.H., Starkstein S.E., et al. Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2008, 23(14):2015-2025.
46. Starkstein S.E., Mayberg H.S., Preziosi T.J., Andrezejewski P., Leiguarda R., Robinson R.G. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992, 4:134-139.
47. Snaith R.P., Hamilton M., Morley S., Humayan A., Hargreaves D., Trigwell P. Br J Psychiatry 1995, 167:99-103.
48. Miller K.M., Okun M.S., Marsiske M., Fennell E.B., Bowers D. Startle reflex hyporeactivity in Parkinson's disease: an emotion-specific or arousal-modulated deficit. Neuropsychologia 2009, 47:1917-1927.
49. Browning L.M., Walker C.G., Mander A.P., West A.L., Madden J., Gambell J.M., et al. Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am J Clin Nutr 2012, 96(4):748-758.
50. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol 2009, 8(4):382-397.
51. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999, 46(4):598-605.
52. McGeer P.L., Schwab C., Parent A., Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration. Ann Neurol 2003, 54(5):599-604.
53. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006, 21(2):404-412.
54. Deutch A.Y., Colbran R.J., Winder D.J. Striatal plasticity and medium spiny neuron dendritic remodeling in parkinsonism. Parkinsonism Relat Disord 2007, 13(Suppl. 3):S251-S258.
55. Sethom M.M., Fares S., Bouaziz N., Melki W., Jemaa R., Feki M., et al. Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2010, 83(3):131-136.
56. Lin Y.C., Koleske A.J. Mechanisms of synapse and dendrite maintenance and their disruption in psychiatric and neurodegenerative disorders. Annu Rev Neurosci 2010, 33:349-378.
57. Kang H.J., Voleti B., Hajszan T., Rajkowska G., Stockmeier C.A., Licznerski P., et al. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat Med 2012, 18(9):1413-1417.
58. Zaja-Milatovic S., Milatovic D., Schantz A.M., Zhang J., Montine K.S., Samii A., et al. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 2005, 64:545-547.